The glucocorticoid receptor signalling in breast cancer: Breast Carcinoma

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 1, 2008, Pages 145-163

  Moutsatsou, Paraskevi ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Breast cancer; Cell signalling; Cell survival; Chemotherapy resistance; Glucocorticoid receptor; Glucocorticoid resistance

Indexed keywords

EID: 41149119366     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00177.x     Document Type: Article

References (165)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53 : 5 26.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1989 63 : 181 7.
3. Herr I, Gassler N, Friess H, Büchler MW. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis. 2007 12 : 271 91.
4. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonoseetron, dexamethasone and aprepitant. J Support Oncol. 2006 4 : 403 8.
5. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol. 2005 11 : 6373 80.
6. Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, Buchler P, Debatin KM, Buchler MW, Friess H, Herr I. Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol. 2006 29 : 1295 301.
7. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006 5 : 933 40.
8. Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy:potentiation of the anti-tumor activity of adriamycin, modulation of cytokine expression and pharmacokinetics. Int J Oncol. 2007 30 : 947 53.
9. Chrousos GP, Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Science's stke. 2005 2005 : pe48.
10. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985 318 : 635 41.
11. Bamberger CM, Bamberger AM, DeCastro M, Chrousos GP. Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest. 1995 95 : 2435 41.
12. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996 17 : 587 609.
13. Kino T, Chrousos GP. Tissue-specific glucocorticoid resistance- hypersensitivity syndromes: multifactorial states of clinical importance. J Allergy Clin Immunol. 2002 109 : 609 13.
14. De Bosscher K, Van den Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003 24 : 488 522.
15. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol. 2003 85 : 457 67.
16. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators:cellular and molecular biology. Endocr Rev. 1999 20 : 321 44.
17. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev. 1998 12 : 1638 51.
18. Oakley RH, Jewell CM, Yudt MR, Bofetiado JA, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem. 1999 274 : 27857 77.
19. Oakley RH, Webster JC, Sar M, Parker CR Jr, Cidlowski JA. Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor. Endocrinology. 1997 138 : 5028 38.
20. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005 18 : 331 42.
21. Duma D, Jewell CM, Cidlowsky JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Molec Biol. 2006 102 : 11 21.
22. Galon J, Franchimont D, Hiroi N, Frey G, Boetner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002 16 : 61 71.
23. Ismaili N, Garabedian MJ. Modulation of glucocorticoid receptor function via phosphorylation. Ann NY Acad Sci. 2004 1024 : 86 101.
24. Hoeck W, Groner B. Hormone-dependent phoshorylation of the glucocorticoid receptor occurs mainly in the amino-terminal transactivation domain. J Biol Chem. 1990 265 : 5403 8.
25. Wang Z, Frederick J, Garabedian MJ. Deciphering the phoshorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem. 2002 277 : 26573 80.
26. Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol. 1997 17 : 3947 54.
27. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA. 1998 95 : 2050 5.
28. Helmberg A, Auphan N, Caelles C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J. 1995 14 : 452 60.
29. Ramdas J, Harmon JM. Glucocorticoid-induced apoptosis and regulation of NF-kappaB activity in human leukemic T cells. Endocrinology. 1998 139 : 3813 21.
30. Chapman MS, Askew DJ, Kuscuoglu U, Miesfeld RL. Transcriptional control of steroid-regulated apop-tosis in murine thymoma cells. Mol Endocrinol. 1996 10 : 967 78.
31. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998 93 : 531 41.
32. Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol. 2004 16 : 553 63.
33. Hsu SC, DeFranco DB. Selectivity of cell cycle regulation of glucocorticoid receptor function. J Biol Biochem. 1995 270 : 3359 64.
34. Hu JM, Bodwell JE, Munck A. Cell cycle-dependent glucocorticoid receptor phosphorylation and activity. Mol Endocrinol. 1994 8 : 1709 13.
35. Abel GA, Wochnik GM, Rüegg J, Rouyer A, Holsboer F, Rein T. Activity of the GR in G2 and mitosis. Mol Endocrinol. 2002 16 : 1352 66.
36. Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB. p38 mitogen-activated protein kinase (MAPK) is a key mediator in gluco-corticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phoshorylation of the human glucocorticoid receptor at serine 211. Molec Endocrinol. 2005 19 : 1569 83.
37. Zuo Z, Urban G, Scammell JG, Dean NM, McLean TK, Aragon I, Honkanen RE. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry. 1999 38.
38. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/ deacetylation of the chaperone. J Biol Chem. 2005 280 : 33792 9.
39. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft Do, Pratt WB, Yao TP. HDAC6 regulates hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005 18 : 601 7.
40. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005 363 : 15 23.
41. Aoyagi S, Archer TK. Modulating molecular chaperone hsp90 functions through reversible acetylation. Trends Cell Biol. 2005 15 : 565 7.
42. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem. 2001 276 : 42714 21.
43. Kino T, Tiulpakov A, Ichijo T, Cheng L, Kozasa T, Chrousos GP. G protein beta interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J Cell Biol. 2005 169 : 885 96.
44. Scheller K, Seibel P, Sekeris CE. Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells. Int Rev Cytol. 2003 222 : 1 61.
45. Moutsatsou P, Psarra AG, Tsiapara A, Paraskevakou H, Davaris P, Sekeris CE. Localization of the glucocorticoid receptor in rat brain mitochondria. Arch Biochem Biophys. 2001 386 : 69 78.
46. Koufali M-M, Moutsatsou P, Sekeris CE, Breen KC. The dynamic localization of the glucocorticoid receptor in rat C6 glioma cell mitochondria. Mol Cell Endocrinol. 2003 209 : 51 60.
47. Sionov RV, Cohen O, Kfir S, Zilberman Y, Yefenof E. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med. 2006 203 : 189 201.
48. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004 64 : 1757 64.
49. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. 2001 276 : 16649 54.
50. Maiyar AC, Phu PT, Huang AJ, Firestone GL. Repression of glucocorticoid receptor transactivation and DNA binding of a glucococrticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol Endocrinol. 1997 11 : 312 29.
51. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 2001 20 : 7108 16.
52. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003 191 : 229 37.
53. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993 75 : 487 93.
54. Noguchi T, Metz R, Chen L, Mattei MG, Carrasco D, Bravo R. Structure, mapping and expression of erp, a growth factor-inducible gene encoding a non-transmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol. 1993 13 : 5195 205.
55. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995 270 : 14843 6.
56. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci. 1994 19 : 470 3.
57. Liu Y, Gorospe M, Yang C, Holbrook NJ. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem. 1995 270 : 8377 80.
58. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem. 2002 277 : 47444 50.
59. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol. 2002 22 : 7802 11.
60. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phos-phatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem. 2005 280 : 4117 24.
61. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol. 2006 20 : 2303 14.
62. Earp HS, Dawson TL, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members:a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995 35 : 115 32.
63. de Cupis A, Favoni RE. Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens. Trends Pharmacol Sci. 1997 18 : 245 51.
64. Murphy LJ, Sutherland RL, Stead B, Murphy LC, Lazarus L. Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res. 1986 46 : 728 34.
65. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev. 1995 8 : 559 89.
66. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999 31 : 637 43.
67. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002 110 : 669 72.
68. Ewing TM, Murphy LJ, Ng ML, Pang GY, Lee CS, Watts CK, Sutherland RL. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer. 1989 44 : 744 52.
69. Sanchez T, Hla T. Structural and functional characteristics of SIP receptors. J Cell Biochem. 2004 92 : 913 22.
70. Hla T. Physiological and pathological actions of sphingosine-1-phosphate. Semin Cell Dev Biol. 2004 15 : 513 20.
71. Huwiler A, Pfeilschifter J. Altering the sphingosine-1-phosphate/Ceramide balance: a promising approach for tumor therapy? Curr Pharmaceut Des. 2006 35 : 4625 35.
72. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol. 2002 71 : 493 511.
73. Van Brocklyn JR, Lee MJ, Menzelev R, Olivera A, Edshall L, Cuvillier O, Thomas DM, Coopman PJ, Thangada S, Liu CH, Hla T, Spiegel S. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol. 1998 142 : 229 40.
74. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem. 2002 277 : 25851 4.
75. Döll F, Pfeilschifter J, Huwiler A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochimica et Biophysica Acta. 2005 72 : 81.
76. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 63 : 5962 9.
77. Sapi E, Flick MB, Rodov S, Gilmore-Hebert M, Kelley M, Rockwell S, Kacinski BM. Independent regulation of invasion and anchorange-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res. 1996 56 : 5704 12.
78. Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vitro intraperitoneal model for experimental human breast cancer metastasis. Clin Exp Met. 2005 22 : 1 9.
79. Chambers SK, Wang Y, Gilmore-Hebert M, Kacinski BM. Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breasts carcinomas in vitro. Steroids. 1994 59 : 514 22.
80. Sapi E, Flick MB, Gilmore-Hebert M, Rodov S, Kacinski BM. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene. 1995 10 : 529 42.
81. Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines. Cancer Res. 1992 52 : 3661 6.
82. Toy EP, Chambers JT, Kacinski BM, Flick MB, Chambers SK. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001 80 : 194 200.
83. Flick MB, Sapi E, Kacinski BM. Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. J Cell Biochem. 2002 85 : 10 23.
84. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001 21 : 952 65.
85. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum- and gluco-corticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem. 2003 278 : 5871 82.
86. Tangir J, Bonafe N, Gilmore-Hebert M, Henegariu O, Chambers SK. SGK1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metast. 2004 21 : 477 83.
87. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006 13 : 293 325.
88. Sengupta S, Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen and estrogen receptors. Ann NY Acad Sci. 2004 1024 : 54 71.
89. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 1992 89 : 7262 6.
90. Maiyar AC, Huang AJ, Phu PT, Cha HH, Firestone GL. P53 stimulates promoter activity of the sgk serum/glucocorticoid-inducible serine/theonine protein kinase gene in rodent mammary epithelial cells. J Biol Chem. 1996 271 : 12414 22.
91. Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM, Honkanen RE. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem. 2003 278 : 9747 53.
92. Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst. 2000 92 : 1717 30.
93. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Cancer Res. 2003 3 : 55 63.
94. Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human Nm23/nucleoside dihos-phate kinases. J Bioenerg Biomembr. 2000 32 : 247 58.
95. MacDonald NJ, Freije JM, Stracke ML, Manrow RE, Steeg PS. Site directed mutagenesis of nm23-H1:mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem. 1996 271 : 25107 16.
96. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 2000 60 : 3414 8.
97. Ouatas T, Clare SE, Hartsough MT, DeLaRosa A, Steeg PS. MMTV-associated transcription factor binding sites increase NM23-H1 metastasis suppressor gene expression in humar breast carcinoma cell lines. Clin Exp Metastasis. 2002 19 : 35 42.
98. Ouatas T, Halverson D, Steeg PS. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast cacinoma cells: new uses for old compounds. Clin Cancer Res. 2003 9 : 3763 72.
99. Hao X, Sun B, Hu L, Lähdesmäki H, Dunmire V, Feng Y, Zhang SW, Wang H, Wu C, Wang H, Fuller GN, Symmans WF, Shmulevich I, Zhang W. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004 100 : 1110 22.
100. Herr I, Buchler MW. New in vivo results support concerns about harmful effects of cortisone drugs in the tretment of breast cancer. Cancer Biol Ther. 2006 5 : 941 2.
101. Herr I, Marme A. Glucocorticoids and progression of breast cancer. Cancer Biol Ther. 2005 4 : 1415 6.
102. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005 365 : 671 9.
103. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995 270 : 16483 6.
104. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 3 : 859 68.
105. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002 4 : E131 6.
106. van Dam H Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene. 2001 20 : 2453 64.
107. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 21 : 7680 9.
108. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T. Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer. 2000 87 : 468 72.
109. Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM. FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat. 2003 77 : 265 75.
110. Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999 84 : 533 8.
111. Green KA, Streuli CH. Apoptosis regulation in the mammary gland. Cell Mol Life Sci. 2004 61 : 1867 83.
112. Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol. 1995 131 : 1095 103.
113. Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD. Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech Dev. 2000 97 : 149 55.
114. Haffner MC, Berlato C, Doppler W. Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia. 2006 11 : 63 3.
115. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kapaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAPI and c-IAP2 to suppress caspase-8 activation. Science. 1998 281 : 1680 3.
116. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996 274 : 787 9.
117. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005 15 : 24 7.
118. Gupta S. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol. 2002 22 : 185 94.
119. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002 13 : 135 41.
120. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998 10 : 573 80.
121. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA. P13-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun. 2000 271 : 342 5.
122. Downward J. Mechanisms and consequence of activation of protein kinase B/Akt. Curr Opin Biol. 1998 10 : 262 7.
123. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998 282 : 1318 21.
124. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requirs the Akt serine-threonine kinase. Nature. 1999 401 : 82 5.
125. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 2002 60 : 867 72.
126. Pagliacci MC, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones. Lymphokine Cytokine Res. 1993 12 : 439 47.
127. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol. 2001 133 : 467 76.
128. Machuca C, Mendoza-Milla C, Cordova E, Mejia S, Covarrubias L, Ventura J, Zentella A. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 levels requires NF-kappaB and is independent from AKT. BMC Cell Biol. 2006 7 : 9 20.
129. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappaB activation. J Biol Chem. 2004 279 : 1615 20.
130. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988 48 : 6121 6.
131. Blask DE, Hill SM, Orstead KM, Massa JS. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis. J Neural Transm. 1986 67 : 125 38.
132. Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl. 1986 21 : 433 49.
133. Ebisawa T, Karne S, Lerner MR, Reppert SM. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophors. Proc Natl Acad Sci USA. 1994 91 : 6133 7.
134. Reppert SM, Godson C, Mahle CD, Weaver DR, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA. 1995 92 : 8734 8.
135. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002 192 : 147 56.
136. Brydon I, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R. Dual signaling of human Mel1a melatonin receptors via Gi2, Gi3 and G9/11 proteins. Mol Endocrinol. 1999 13 : 2025 38.
137. Ram PT, Kiefer T, Silverman M, Song Y, Brown GM, Hill SM. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factor. Mol Cell Endocrinol. 1998 141 : 53 64.
138. Kiefer TL, Yuan L, Ram PT, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 2002 71 : 37 45.
139. Kiefer T, Lai L, Yuan L, Dong C, Burow ME, Hill SM. Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins. J Pineal Res. 2005 38 : 231 9.
140. Fryer CJ, Nordeen SK, Archer TK. Antiprogestins mediate differential effects on glucocorticoid receptor remodeling of chromatin structure. J Biol Chem. 1998 273 : 1175 83.
141. Fryer CJ, Kinyamu HK, Rogatsky I, Garabedian MJ, Archer TK. Selective activation of the glucocorticoid receptor by steroid antagonists in human breast cancer and osteosarcoma cells. J Biol Chem. 2000 275 : 17771 7.
142. Wan Y, Nordeen SK. Overlapping but distinct profiles of gene expression elicited by glucocorticoids and progestins. Recent Prog Horm Res. 2003 58 : 199 226.
143. Wan Y, Nordeen SK. Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol. 2002 16 : 1204 14.
144. Leo JC, Guo C, Woon CT, AW SE, Lin VC. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology. 2004 145 : 1314 21.
145. Krishnan AV, Swami S, Feldman D. Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 2001 77 : 29 37.
146. Meyer ME, Gronemeyer H, Turcotte B, Bocquel MT, Tasset D, Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell. 1989 57 : 433 42.
147. Ankenbauer W, Strahle U, Schutz G. Synergistic action of glucocorticoid and estradiol responsive elements. Proc Natl Acad Sci USA. 1988 85 : 7526 30.
148. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in Mdm2 protein expression. Mol Cell Biol. 2003 23 : 5867 81.
149. Deroo B, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK. Proteasonal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol. 2002 22 : 4113 23.
150. Krueger J, Ray A, Tamm I, Sehgai PB. Expression and function of interleukin-6 in epithelial cells. J Cell Biochem. 1991 45 : 327 34.
151. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Reg. 2006 15 : 179 85.
152. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007 102 : 129 35.
153. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 2006 97 : 1044 9.
154. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine and Growth Factor Rev. 2007 18 : 45 56.
155. Lipka C, Mankertz J, Fromm M, Lubbert H, Buhler H, Kuhn W, Ragosch V, Hundertmark S. Impairment of the antiproliferative effect of glucocorticosteroids by 11beta-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast cancer cells. Horm Metab Res. 2004 36 : 437 44.
156. Fazekas AG, MacFarlane JK. Macromolecular binding of glucocorticoids in human mammary carcinoma. Cancer Res. 1977 37 : 640 5.
157. Ioannidis C, Papamichail M, Agnanti N, Garas J, Tsawdaroglou N, Sekeris CE. The detection of glucocorticoid receptors in breast cancer by immunocytochemical and biochemical methods. Int J Cancer. 1982 29 : 147 52.
158. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do H M, Aitken SC. Distribution, frequency and quantitative analysis of estrogen, progesterone, androgen and glucocorticoid receptors in human breast cancer. Cancer Res. 1979 39 : 1447 54.
159. Liu SH, Otal-Brun M, Webb TE. Glucocorticoid receptors in human tumors. Cancer Lett. 1980 10 : 269 75.
160. Smith RA, Lea RA, Curran JE, Weinstein SR, Griffiths LR. Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue. Breast Cancer Res. 2003 5 : R9 12.
161. Smith RA, Lea RA, Weinstein SR, Griffiths LR. Progesterone, glucocorticoid, but not estrogen receptor mRNA is altered in breast cancer stroma. Cancer Lett. 2007 255 : 77 84.
162. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH, Huang CS, Chang KJ, Yao YT. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol. 2006 209 : 317 27.
163. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006 19 : 617 21.
164. Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol. 2006 246 : 142 6.
165. Tasker JG, Di S, Malcher-Lopes R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology. 2006 147 : 5549 56.